EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026

Thursday, August 3, 2017 Environmental Health
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Aug. 2, 2017 /PRNewswire/ -- EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026SummaryGHD

is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during
adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development.Read the full report: http://www.reportlinker.com/p03249270/EpiCast-Report-Growth-Hormone-Deficiency-Epidemiology-Forecast-to.htmlIn the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26%. Our epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan.In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13%, of all cases of GHD in the 7MM. Our epidemiologists maintained a consistent forecast methodology across all the 7MM, which allows for comparison between each of the seven markets. Due to the limited availability of market-specific epidemiological studies available, further research is needed to better understand inter-market variations of the epidemiological parameters.The report "EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and global trends for GHD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex from 2016 to 2026. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD (COGHD) and adult onset GHD (AOGHD).Scope- The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.- The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.Reasons to buyThe GHD EpiCast report will allow you to -- Develop business strategies by understanding the trends shaping and driving the global GHD market.- Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.Read the full report: http://www.reportlinker.com/p03249270/EpiCast-Report-Growth-Hormone-Deficiency-Epidemiology-Forecast-to.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/epicast-report-growth-hormone-deficiency---epidemiology-forecast-to-2026-300498628.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook